Eli Lilly news from FiercePharma
NewsALSO NOTED: Botox slowdown doesn't dampen Allergan's Q1; Shandong Lunan launches new API plant
> Allergan more than doubled first-quarter profits to $111 million as strong sales of its eye, skin, and nerve drugs offset lower domestic sales growth of its Botox cosmetic treatment. Read more...
AAMC: Ban pharma gifts at med schools
Will all medical schools bar the door to pharma giveaways? The Association of American Medical Colleges hopes so. After two years of study, the influential group drafted a policy that would ban drug Read more...
Profits rise at Novartis, Merck, Lilly
Good financial results from three Pharma biggies should cheer up those market-watchers who moaned their way through much of last week. Sure, a couple of the profit leaps came at least in part from Read more...
Lilly wants to buy out 500 workers
Add up to 500 Eli Lilly workers to the pharma layoff toll. The Indianapolis-based pharma plans to offer buyout packages Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Judge wary of certifying Zyprexa classes
Score one for Eli Lilly in federal court. A district judge says he probably won't give class-action status to patients and insurers who paid for Zyprexa for FDA-approved uses. And he doesn't expect Read more...
Strategy execs advise Big Pharma
How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At least Read more...
Arms twisted, pharma promises disclosure
Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...
ALSO NOTED: Big Biotech emerges as a shelter in economic storm; Arseus recalls compounded heparin;
> While just about every category of stocks has been hammered in recent months, biotech has edged up. Investors have been betting that the biotech business model, which relies on breakthrough Read more...
| Press ReleasesLilly Completes Final Phase of Its Indianapolis Biotechnology ComplexLilly Completes Final Phase of Its Indianapolis Biotechnology ComplexMay 12, 2008 Completion honors Lilly's commitment to the community and its biotech pipelineINDIANAPOLIS, May 12, 2008 Read more... FDA Approves Cialis (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction FDA Approves Cialis (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction -Approval Makes Available New Daily Dosing Option for the Treatment of ED- INDIANAPOLIS, Jan 08, 2008 -- Read more... Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel, to FDA Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Read more... PRESS RELEASE: Galapagos NV in Osteoporosis Deal with Eli Lilly and Company Galapagos NV in Osteoporosis Deal with Eli Lilly and Company Mechelen, Belgium; 19 December 2007 - Galapagos announced today that it has entered into a global collaboration agreement with Eli Lilly Read more... PRESS RELEASE: Ambrx Announces Drug Discovery Alliance With Eli Lilly and Company Ambrx Announces Drug Discovery Alliance With Eli Lilly and Company Ambrx to Collaborate with Lilly to Discover Protein and Antibody Drug Candidates Targeting Multiple Therapeutic Areas Using Ambrx's Read more... |
Get more Eli Lilly coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight